Novartis's canakinumab failed to help COVID-19 patients survive without invasive ventilation compared with standard therapy, the Swiss drugmaker said on Friday, dashing hopes the arthritis drug could be repurposed during the pandemic. The medicine, approved as Ilaris for juvenile arthritis and other conditions, also did not meet its key secondary endpoint of reducing COVID-19 mortality in a late-phase clinical trial, the Basel-based drugmaker said. Novartis has hoped 11-year-old canakinumab, with $671 million in sales last year, would help COVID-19 patients hit by inflammatory reactions.
Hence then, the article about novartis arthritis drug fails to help covid 19 patients was published today ( ) and is available onYahoo ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Novartis arthritis drug fails to help COVID-19 patients )